A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (NCT06892548)
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (91 Sites)
Showing the first 25 of 91 sites.
- Mayo Clinic Arizona — Phoenix, Arizona
- Precision NextGen Oncology and Research Center — Beverly Hills, California
- Cedars Sinai Medical Center — Los Angeles, California
- UCLA - David Geffen School of Medicine — Santa Monica, California
- University of Colorado Cancer Center — Aurora, Colorado
- Mayo Clinic in Florida — Jacksonville, Florida
- University of Iowa Hospitals & Clinics PARENT — Iowa City, Iowa
- Mayo Clinic-Rochester — Rochester, Minnesota
- Regional Cancer Care Associates — Belleville, New Jersey
- John Theurer Cancer Center at Hackensack UMC — Hackensack, New Jersey
- Memorial Sloan Kettering Cancer Center (MSKCC) — New York, New York
- Icahn School of Medicine at Mount Sinai PRIME — New York, New York
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center — Cleveland, Ohio
- Texas Oncology - DFW — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology - Northeast — Tyler, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Chris O'Brien Lifehouse — Camperdown, New South Wales
- Flinders Medical Centre — Bedford Park, South Australia
- Bendigo Hospital — Bendigo, Victoria
- Barwon Health — Geelong, Victoria
- Sunshine Hospital — Saint Albans, Victoria
- St John of God Subiaco Hospital — Subiaco, Western Australia
- Anhui Provincial Cancer Hospital — Hefei, Anhui
- Beijing Cancer Hospital — Beijing, Beijing Municipality
📞 Contact the Study Coordinator
Phone: (496) 131-9084
Email: patients@biontech.de
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Lung Cancer
Explore by condition: All Advanced Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.